GHRP-2 and GHRP-6 are growth hormone-releasing peptides that predate the newer generation of secretagogues this newsletter has covered more often — older in both their research history and their reputation within the community, for reasons that trace back to a specific side effect.
The Appetite Problem
Both compounds, and GHRP-6 especially, reliably stimulate appetite as part of their mechanism — a well-documented effect that’s actually been studied clinically in cachexia (wasting illness) populations, but one that makes them a poor fit for anyone using them alongside a fat-loss goal.
“The appetite effect isn’t a rumor — it’s the most clinically documented thing about these two compounds. It’s just usually the opposite of what buyers want.”
— an endocrinology researcher who reviewed the comparative literature for this pieceWhy Ipamorelin Displaced Them in Community Use
Ipamorelin was developed partly to retain the growth-hormone-releasing effect while reducing the appetite stimulation and cortisol/prolactin effects associated with the older GHRPs — a real pharmacological refinement, not just marketing repositioning.
Where the Older Compounds Still Have a Case
The clinical cachexia research on GHRP-6’s appetite effect is a legitimate, if narrow, evidence base — for a population trying to gain weight under medical supervision, not for most of the market now buying it for other reasons.